Genprex, Inc. (GNPX) Wednesday announced the expansion of its non-clinical programs into new indications to study TUSC2, the tumor suppressor gene used in its drug candidate, Requorsa, and NPRL2, another tumor suppressor gene.
The new indications being evaluated include ALK-positive lung cancer and other additional programs. ALK-EML4 positive translocated lung cancer is a subset of non-small cell lung cancer that impacts young and relatively healthy individuals.
TUSC2 is a tumor suppressor gene that is frequently deleted in lung cancer.
The company said it plans to do the expansion through Sponsored Research Agreements and Material Transfer Agreements with multiple academic research collaborators.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.